This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or registerLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



AboutAboutAntibacterialsAntifungalsAntimicrobial Resistance(AMR)Our CommitmentOur CommitmentPfizer’s Heritage in AMR
What is AMR?

Antimicrobial resistance (AMR) is one of the biggest threats to global health today and urgently needs to be addressed. It can affect anyone, of any age, in any country.1

AMR is a silent threat, but it is already here and urgently needs to be addressed. If AMR continues to rise unchecked, minor infections could become life-threatening, serious infections could become impossible to treat and many routine medical procedures could become too risky to perform.1,2​

Who can be impacted by AMR?

A continued rise in AMR could cause 10 million deaths per year across the globe by 2050 – more than currently die from cancer.2​

The COVID-19 pandemic has reinforced a need to invest in diagnostics, infection prevention, surveillance, and stewardship now to help prevent future global health crises. We must take action to help protect our futures.3-5​

What is the global impact of AMR?

It is estimated that 1.27 million deaths globally were caused by bacterial AMR in 2019. If no solution is found, this devastating impact is likely to worsen.6

AMR Facts

Antimicrobial medicines (antibiotics that target bacteria, antivirals that target viruses, and antifungals that target fungi) are among the most precious medical resources the world has ever known.7​

Antibiotics have drastically changed modern medicine, extending the average human lifespan by 23 years.8​

Similarities can be drawn between the COVID-19 pandemic and AMR pathogens, including the need for strong public health and preparedness measures.​

COVID-19 has threatened the progress made against resistant pathogens and impacted our ability to address AMR, making AMR an even more pressing threat.9​

Only three classes of commonly prescribed antifungal drugs currently exist, so antifungal resistance can severely limit treatment options.10​

No novel class of antibiotic has been discovered for almost 40 years. There are only 40 to 50 antibiotics in clinical development at present, while thousands of potential immuno-oncology therapies are currently being evaluated. The rate of innovation is insufficient to meet current and future needs.11​

References:World Health Organization. Antibiotic resistance factsheet. July 2020. Available at: Last accessed January 2023.Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. May 2016. Available at: Last accessed January 2023.Pelfrene E, Botgros R, Cavaleri M. Antimicrobial multidrug resistance in the era of COVID‑19: a forgotten plight? Antimicrob Resist Infect Control. 2021;10:21.​Yam ELY. COVID-19 will further exacerbate global antimicrobial resistance. J Travel Med. 2020;27:taaa098.​Langford B. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Available at: Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis - Clinical Microbiology and Infection. Last Accessed January 2023. ​Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655​Review on Antimicrobial Resistance. Tackling a crisis for the health and wealth of nations. December 2014. Available at: Last accessed January 2023.Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol. 2019;51:72-80​Clancy CJ, Buehrle DJ, Nguyen MH. PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates. JAC Antimicrob Resist. 2020;2:dlaa049.​Centers for Disease Control and Prevention (CDC). Antifungal resistance. Available at: Last accessed January 2023.Pew Charitable Trusts. (2021). Tracking the Global Pipeline of Antibiotics in Development. Available at: Last accessed January 2023.
Support your patientHaemoassist®2

Watch our video to learn more about the Haemoassist®2 innovative haemophilia therapy management tool.

Watch video
HemMobile® The HemMobile® App uses innovative tools and technologies to help your patients track their bleeds and infusions, and share consolidated reports with their healthcare team. Find out more

[Inclusion of this page will depend on local availability of Haemoassist®2, which is not available in all markets. Please consider during local review and approval process]

PP-UNP-IRL-0350 Date of Preparation: January 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.